GE HealthCare stock gets Needham's USD 93.00 target

Published on 09/28/2026 at 12:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GE HealthCare stock posted Q2 revenue of USD 5.295 billion and adjusted EPS of USD 1.13. Needham set a USD 93.00 target on September 22, 2026.

Techniker bedient MRT-Scanner in hellem Krankenhaus-Untersuchungsraum mit Flurblick — GE HealthCare US36266G1076 zeigt einen modernen MRT-Scanner im hellen klinischen Krankenhaus mit Techniker, Illustration mit AI erstellt.

GE HealthCare (ISIN US36266G1076) stock was last at USD 66.63 on Nasdaq on September 25, 2026, at 4:00 p.m. ET, up 0.38 percent from the prior close. The latest analyst catalyst came on September 22, 2026, when Needham initiated coverage with a Buy rating and a USD 93.00 price target, as CNBC reported.

Needham sees a USD 93.00 target

Needham's call places valuation at the center of the GE HealthCare story. The firm linked its outlook to faster growth in advanced imaging systems and expected stronger earnings growth over the next year, according to CNBC.

The broader analyst picture is constructive but not unanimous. MarketBeat reported on September 23, 2026, that 22 analysts were split between 11 Buy and 11 Hold ratings, producing a Moderate Buy consensus and an average target of USD 78.39.

Q2 revenue reached USD 5.295 billion

GE HealthCare's Q2 2026 results provide the operating evidence behind the debate. Revenue reached USD 5.295 billion, up 5.8 percent from the same quarter a year earlier, while adjusted EPS came in at USD 1.13 versus a USD 1.04 consensus estimate, according to Investing.com on September 22, 2026.

Organic orders increased 11.1 percent year over year in the same quarter, the fastest growth rate since the company's spin-off, the report said. That order figure matters because capital equipment demand can influence both future revenue and the valuation multiple investors assign to GE HealthCare.

Stock remains below its yearly high

At USD 66.63, the stock stood USD 23.14 below its 52-week high of USD 89.77 and USD 7.88 above its 52-week low of USD 58.75 on September 25, 2026. The session volume was 4,159,465 shares, while market capitalization stood at USD 30.1 billion.

The company operates in healthcare equipment and medical devices across imaging, ultrasound, patient care solutions and pharmaceutical diagnostics. For investors, the key tension is clear: Q2 revenue and order growth offer measurable operating support, while the share price remains materially below its yearly high and the analyst consensus target of USD 78.39.

USD 66.63 remains the reference price

GE HealthCare stock was last at USD 66.63 on Nasdaq on September 25, 2026, at 4:00 p.m. ET, with a daily change of 0.38 percent and a 52-week range of USD 58.75 to USD 89.77.